|Mr. Scott William Drake||Pres, CEO & Director||770.08k||N/A||1968|
|Mr. Shahriar Matin||Chief Operating Officer||526.46k||N/A||1975|
|Mr. James Alecxih||Chief Commercial Officer||315k||N/A||1965|
|Mr. Brian Knaley||Interim Chief Financial Officer||N/A||N/A||1970|
|Dr. James F. Dempsey||Chief Scientific Officer & Director||N/A||N/A||1971|
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image-guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. ViewRay, Inc. serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. The company markets its MRIdian through a direct sales force in North America. ViewRay, Inc. has collaboration agreements with Elekta AB and Medtronic. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
ViewRay, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 10.